top of page


Welcome to the press portal for Advanced Therapies Week, the last one in Miami - January 16th - 19th 2024 I Miami Beach Convention Center.  

This portal will evolve in to IB.TV where we will continue to provide content post show and beyond. So keep you’ re eyes out for information on that.

For ATW24 - here you can find all the latest news direct from the conference; press releases, interviews from the floor, blog and video updates. Make sure to check in regularly.

We have a great list of media covering the show. Feel free to connect with the IBt team if you are a journalist or exhibitor and require any assistance during the show.

Advanced Therapies Week is an event like no other. With networking opportunities taking place from morning to night, we provide attendees with an outstanding experience that entails thought-provoking content, high-profile speakers, and unmissable networking events.

IB Communications is the leading international communications agency in the CGT space. We hold specific expertise in the biotech and biopharma sectors and mid-size pharma.

Press office contact: / +44 (0) 7707 560846 or +1 617 331 7198

Scroll down for latest news and press releases...

IB Communications is a leading international communications agency specialising in healthcare and life sciences. We hold specific expertise in the biotech and biopharma sectors, including immunotherapy, regenerative medicine, ATMPs and cell and gene therapy. 


Press office contact: / +44 (0) 7707 560846 or +1 617 331 7198.

Advanced Therapies Week logo
Reaction from around the show
Content will be posted as its created and available

Ryan Leahy - Phacilitate

Josh Ludwig - ScaleReady

Anki Miller - LifeArc

Isabel Cameron - BioPharma Reporter

Joel Eichmann - Green Elephant BioTech

Azra Benson - Virica BioTech

Natalia Elizalde - Vive BioTech

Stella Vnook - Likarda

Ken Gordon - Amadeus

Justin Irizarry - Priya Baraniak - OrganaBio

Daily Sethi - Terumo

Dominique Yon - CellQuest

Matthew Lakelin - TrakCel

Lindsay Davies - Nextcell


Please contact us if you believe there are mistakes in these videos - we'll do our best to rectify them ASAP

2024 Advanced Therapies Week - Press Releases

WEST SACRAMENTO, Calif., January, 2024 /PRNewswire/ -- Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, a portfolio company of BelHealth

Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the launch of a new human AB serum product for the cell therapy and regenerative medicine markets.

Bluecrux, a leader in value chain consulting and technologies, is excited to announce a groundbreaking update to their innovative scheduling and capacity planning software platform, Binocs. This feature

release sets a new industry standard for Cell and Gene Therapy manufacturing and propels Binocs to the forefront of must-have solutions to support developers and CDMOs in the ATMP space.

3P Innovation Announces Delivery of First Truly Aseptic, GMP Cryovial Filling Platform

The CryoFil is designed to automate the critical process of filling cryovials with cell and gene therapy products, ensuring the highest levels of sterility and consistency.

January 3, 2024; Warwick, UK – 3P Innovation, a leading provider of automated solutions for the pharmaceutical and biotechnology industries, today announced the delivery of its first truly aseptic, GMP cryovial filling platform.

Charles River Launches Rep/Cap Plasmids to Streamline Adeno-Associated Viral Vector Manufacturing

January 16, 2024 at 8:00 AM EST

Off-the-shelf Rep/Cap simplifies gene therapy supply chains with immediate availability

WILMINGTON, Mass.--(BUSINESS WIRE)--Jan. 16, 2024-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline adeno-associated virus (AAV)-based gene therapy programs.

WhiteLab Genomics and Siren Biotechnology Announce Strategic Partnership to Accelerate AI-Powered Advancements in Gene Therapy

● WhiteLab Genomics and Siren Biotechnology to engage in a strategic partnership to develop an AI-powered indication discovery platform for AAV immuno-gene therapies for cancer.

● WhiteLab Genomics, working in collaboration with Siren Biotechnology’s research and development team, will build what is believed to be the first ever AI-powered indication discovery platform for AAV gene therapies.

● The collaboration will accelerate the identification of new target indication candidates for Siren Biotechnology’s Universal Immuno-Gene Therapies for CancerTM.

CellQuest launches Early Access Program with first CosyNest automated CAR-T manufacturing partner

New program gives partners a first look at the CosyNest platform for rapid, scalable CAR-T manufacturing ahead of commercialization, with data supporting CellQuest’s regulatory master files

OrganaBio Named Translation Award Finalist for Supporting CAR- NKT Cell Therapies into Clinical Trials

● OrganaBio has developed GMP-quality supply chains and processes to ensure ample availability of donor-derived cells for clinical trials of first-in-class allogeneic CAR-NKT cell therapies

● The Translator of the Year award winner will be announced this Thursday at Phacilitate’s Advanced Therapies Week

TrakCel launches Consultancy Services to share extensive cell and gene therapy process development expertise

● TrakCel Consultancy Services will leverage company’s experience to help early-stage developers reduce inefficiencies and enable flexible growth

● Expertise based on 12 years of helping develop and manage processes for more than 15 therapy classes, and supporting four commercial therapies

Cellply launches its end-to-end single cell potency characterization platform VivaCyte

• Integrates potency analysis and immunophenotyping to streamline cell

therapy R&D

• Fully automated, standalone platform with single-cell resolution


BOLOGNA, Italy, January 17, 2024 – Cellply S.r.l. (Cellply) a leading developer of analytical tools for research and quality control within the “Cell Therapy” sector, today announced the launch of its flagship product VivaCyte®.


Fondazione Telethon is also working to make a new gene therapy for the Wiskott-Aldrich syndrome available for early access

Milan, January 18th, 2024 – Fondazione Telethon is the first non-profit organization to take on the commercialization of Strimvelis, a gene therapy for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID), to continue ensuring access to all eligible patients in Europe.

Whilst every effort is made to ensure data accuracy we acknowledge that mistakes do happen.

If you believe there are corrections required to any of the information contained within these Press Releases, please email:

Images from this years show

'Great shame this is the last year in Miami but I'm sure the guys at Phacilitate will knock out the park in San Diego, they always put on a great event"

partner villiage.jpg
Innovation zone.jpg
mardi gras.jpg
Super plenary.JPG
bottom of page